Premium
Methoxypoly(ethylene glycol) ‐block‐ Poly( L ‐glutamic acid)‐Loaded Cisplatin and a Combination With iRGD for the Treatment of Non‐Small‐Cell Lung Cancers
Author(s) -
Song Wantong,
Li Mingqiang,
Tang Zhaohui,
Li Quanshun,
Yang Yan,
Liu Huaiyu,
Duan Taicheng,
Hong Hua,
Chen Xuesi
Publication year - 2012
Publication title -
macromolecular bioscience
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.924
H-Index - 105
eISSN - 1616-5195
pISSN - 1616-5187
DOI - 10.1002/mabi.201200145
Subject(s) - cisplatin , ethylene glycol , chemistry , hela , in vivo , a549 cell , micelle , glutamic acid , cancer research , cell growth , toxicity , pharmacology , biophysics , chemotherapy , cell , biochemistry , medicine , biology , amino acid , organic chemistry , aqueous solution , microbiology and biotechnology
CDDP is loaded into methoxypoly(ethylene glycol)‐ block‐ poly( L ‐glutamic acid) (mPEG ‐b‐ PLG), and a combination with iRGD is applied for NSCLC chemotherapy. The CDDP‐loaded micelles show sustained cisplatin release in PBS, dose‐ and time‐dependent inhibition to HeLa and A549 cell proliferation, and no apparent hemolysis activities. In in vivo studies using subcutaneous NSCLC xenograft models (A549), both free CDDP and CDDP‐loaded micelles show an evident anti‐tumor effect. However, the toxicity of CDDP is significantly reduced in the cases of CDDP‐loaded micelles and co‐administration with iRGD, and the survival time is prolonged by over 30%. Therefore, mPEG ‐b‐ PLG‐loaded cisplatin and the combination with iRGD provides a promising new therapy for NSCLC.